Compare Progressive Corp (PGR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs TG Therapeutics Inc — how do they compare? Progressive Corp trades at $217.6 (market cap $126.95B), while TG Therapeutics Inc trades at $54.95 (market cap $8.16B). The key difference: Progressive Corp is far larger — about 15.6× TG Therapeutics Inc's market cap, and Progressive Corp pays a 0.18% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and TG Therapeutics Inc for 16 Days on average.
| PGR | TGTX | |
|---|---|---|
Market Cap | $126.95B | $8.16B |
Volume | 2,749,438 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $242.16 | $59.06 |
52-Week Low | $190.40 | $26.94 |
Typical Hold Time | 81 Days | 16 Days |
Enterprise Value | $135.16B | $8.37B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $218.51, up 2.05% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with 12.85% net income margin and 34.94% ROE, supported by consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026 with EPS of $4.85 versus $4.64 expected, though Q1 2026 slightly missed. Analyst consensus price target is $222.23 with 38.1% buy ratings.
PGR presents a favorable risk-reward profile with upside to consensus targets, though near-term overbought RSI conditions warrant caution. The insurance giant's telematics advantage and underwriting discipline provide competitive moat, while intensifying auto insurance competition represents the primary business risk. Current valuation at 10.97 P/E appears reasonable given growth trajectory and profitability metrics.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
